520 related articles for article (PubMed ID: 37043676)
41. Probe Cocktail to Assess Transporter Function in Sandwich-Cultured Human Hepatocytes.
Guo C; Brouwer KR; Stewart PW; Mosley C; Brouwer KLR
J Pharm Pharm Sci; 2019; 22(1):567-575. PubMed ID: 31804919
[TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
[TBL] [Abstract][Full Text] [Related]
43. In Vitro Interactions of Epacadostat and its Major Metabolites with Human Efflux and Uptake Transporters: Implications for Pharmacokinetics and Drug Interactions.
Zhang Q; Zhang Y; Boer J; Shi JG; Hu P; Diamond S; Yeleswaram S
Drug Metab Dispos; 2017 Jun; 45(6):612-623. PubMed ID: 28283500
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.
Lepist EI; Gillies H; Smith W; Hao J; Hubert C; St Claire RL; Brouwer KR; Ray AS
PLoS One; 2014; 9(1):e87548. PubMed ID: 24498134
[TBL] [Abstract][Full Text] [Related]
45. Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects.
Mohamed MF; Coppola S; Feng T; Camp HS; Kim E; Othman AA
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1335-1344. PubMed ID: 34109764
[TBL] [Abstract][Full Text] [Related]
46. Prediction of drug-drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling.
Chang M; Bathena S; Christopher LJ; Shen H; Roy A
Cancer Chemother Pharmacol; 2022 Mar; 89(3):383-392. PubMed ID: 35147740
[TBL] [Abstract][Full Text] [Related]
47. Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.
Wang Q; Zheng M; Leil T
CPT Pharmacometrics Syst Pharmacol; 2017 Apr; 6(4):228-238. PubMed ID: 28296193
[TBL] [Abstract][Full Text] [Related]
48. Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling.
Costales C; Lin J; Kimoto E; Yamazaki S; Gosset JR; Rodrigues AD; Lazzaro S; West MA; West M; Varma MVS
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1018-1031. PubMed ID: 34164937
[TBL] [Abstract][Full Text] [Related]
49. A pharmacokinetic drug-drug interaction study between rosuvastatin and emvododstat, a potent anti-SARS-CoV-2 (COVID-19) DHODH (dihydroorotate dehydrogenase) inhibitor.
Morton TL; Laskin OL; Kaushik D; Lee L; Ma J; Kristensen A; O'Keefe K; Golden L; Klein M; Kong R
Pharmacol Res Perspect; 2023 Apr; 11(2):e01076. PubMed ID: 36938928
[TBL] [Abstract][Full Text] [Related]
50. Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner.
Alam K; Farasyn T; Crowe A; Ding K; Yue W
PLoS One; 2017; 12(11):e0186924. PubMed ID: 29107984
[TBL] [Abstract][Full Text] [Related]
51. Digoxin is not a substrate for organic anion-transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium-dependent transporter expressed in HEK293 cells.
Taub ME; Mease K; Sane RS; Watson CA; Chen L; Ellens H; Hirakawa B; Reyner EL; Jani M; Lee CA
Drug Metab Dispos; 2011 Nov; 39(11):2093-102. PubMed ID: 21849517
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of hepatic uptake transporters by flavonoids.
Mandery K; Balk B; Bujok K; Schmidt I; Fromm MF; Glaeser H
Eur J Pharm Sci; 2012 May; 46(1-2):79-85. PubMed ID: 22394605
[TBL] [Abstract][Full Text] [Related]
53. The potential of Sutherlandia frutescens for herb-drug interaction.
Fasinu PS; Gutmann H; Schiller H; James AD; Bouic PJ; Rosenkranz B
Drug Metab Dispos; 2013 Feb; 41(2):488-97. PubMed ID: 23209194
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of human drug transporter activities by succinate dehydrogenase inhibitors.
Kerhoas M; Le Vée M; Carteret J; Jouan E; Tastet V; Bruyère A; Huc L; Fardel O
Chemosphere; 2024 Jun; 358():142122. PubMed ID: 38663675
[TBL] [Abstract][Full Text] [Related]
55. Dissecting the Contribution of OATP1B1 to Hepatic Uptake of Statins Using the OATP1B1 Selective Inhibitor Estropipate.
Zhang Y; Panfen E; Fancher M; Sinz M; Marathe P; Shen H
Mol Pharm; 2019 Jun; 16(6):2342-2353. PubMed ID: 31039308
[TBL] [Abstract][Full Text] [Related]
56. Influence of Tyrosine Kinase Inhibition on Organic Anion Transporting Polypeptide 1B3-Mediated Uptake.
Hove VN; Anderson K; Hayden ER; Pasquariello KZ; Gibson AA; Shen S; Qu J; Jin Y; Miecznikowski JC; Hu S; Sprowl JA
Mol Pharmacol; 2022 Jun; 101(6):381-389. PubMed ID: 35383108
[TBL] [Abstract][Full Text] [Related]
57. Rhinacanthin-C Mediated Herb-Drug Interactions with Drug Transporters and Phase I Drug-Metabolizing Enzymes.
Dunkoksung W; Vardhanabhuti N; Siripong P; Jianmongkol S
Drug Metab Dispos; 2019 Oct; 47(10):1040-1049. PubMed ID: 31399508
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo.
Song IS; Kong TY; Jeong HU; Kim EN; Kwon SS; Kang HE; Choi SZ; Son M; Lee HS
BMC Complement Altern Med; 2014 Jul; 14():251. PubMed ID: 25034211
[TBL] [Abstract][Full Text] [Related]
59. Interactions between Oroxylin A with the solute carrier transporters and ATP-binding cassette transporters: Drug transporters profile for this flavonoid.
Ren G; Qin Z; Yang N; Chen H; Fu K; Lu C; Lu Y; Li N; Zhang Y; Chen X; Zhao D
Chem Biol Interact; 2020 Jun; 324():109097. PubMed ID: 32305507
[TBL] [Abstract][Full Text] [Related]
60. Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice.
Biali ME; Auvity S; Cisternino S; Smirnova M; Hacker M; Zeitlinger M; Mairinger S; Tournier N; Bauer M; Langer O
Mol Pharm; 2023 Nov; 20(11):5877-5887. PubMed ID: 37883694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
